Peptide Synthesis Market Size to Exceed USD 866.7 Mn by 2032

The Peptide Synthesis Market, estimated at USD 519.0 Mn in 2025, is expected to exhibit a CAGR of 7.6% and reach USD 866.7 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key market players are focused on adopting various business development activities, such as funding  and others, which in turn is expected to propel market growth over the forecast period. For instance, on December 14, 2023, Amide Technologies, a biotech that synthesizes challenging peptides, announced that it had begun commercializing its novel peptide manufacturing platform. The company also announced it has raised US$ 16.5 million in total funding to date, which includes a US$ 7.5 million Series A Extension investment closed in July 2023 led by Engine Ventures, an investment firm, with participation from Forcefield Venture Fund, a venture capital firm. Previous rounds included a US$ 3.5 million Series A, also led by Engine Ventures, and a US$ 5.5 million Seed Round led by Biological Engineering Ventures, a venture capital firm.

Global Peptide Synthesis Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.

Lockdowns or shutdowns imposed in many countries had a negative impact on the economy of the private healthcare sector globally.

Lockdowns resulted in the closure of industrial establishments, except for the manufacturing of essential commodities, and disruptions in the supply chain of healthcare products.

On the other hand, peptides were increasingly being developed and repurposed in search of therapeutics for the treatment of the COVID-19 pandemic, which propelled market growth. For instance, as per the August 2022 update from Clinical Trials.gov, there is a robust pipeline of peptide-based therapeutics under development specifically targeting COVID-19. This includes over 100 peptide candidates geared toward various treatment aspects, with 15 of these synthetic peptides focusing on addressing acute respiratory distress syndrome (ARDS)—a critical and potentially fatal condition that impairs pulmonary oxygenation capabilities—and other respiratory complications induced by the SARS-CoV-2 virus. The development activities in this sector reflect a concerted response to the ongoing demand for effective COVID-19 therapeutics, representing a significant area of investment and interest within the pharmaceutical industry.

Global Peptide Synthesis Market: Key Developments

In January 2022, CordenPharma, a company specializing in pharmaceutical manufacturing, has recently entered into a partnership with PeptiSystems, innovators in the field of peptide and oligonucleotide production technology. PeptiSystems is known for developing instruments that facilitate the process development and manufacturing of these therapeutics using flow-through column technology. Acknowledging the significant waste generated from producing peptides in quantities exceeding 100 kilograms annually, the CordenPharma Peptide Center of Excellence located in Frankfurt, Germany, has integrated PeptiSystems' pioneering technology. This move aims to diminish the environmental impact and enhance the Process Mass Intensity (PMI) associated with peptide production methods.

In September 2021, CEM Corporation, the leading provider of microwave instrumentation, and AmbioPharm, Inc., a peptide manufacturing & development services offering company, announced the formation of a partnership for the production of Good Manufacturing Practices peptides for the global market. The partnership will involve an exclusive use of CEM’s large-scale microwave peptide synthesis technology for the production of Good Manufacturing Practices peptides up to multi-kilogram quantities using proprietary scalable reactors. The key benefits of this new relationship are extremely rapid production times, the ability to efficiently produce more difficult peptide sequences, and the ability to incorporate green chemistry protocols. This partnership will enable rapid and efficient production of peptide new chemical entities (NCE’s) using the latest technologies available. With this agreement, AmbioPharm has commenced peptide synthesis operations in its North Augusta facility to better serve customers with expedited microwave synthesis capabilities.

In July 2020, CordenPharma, a Contract Development & Manufacturing Organization (CDMO), recently declared an increase in its solid-phase peptide synthesis production capabilities within its Boulder, CO-based facility, CordenPharma Colorado, which is dedicated to following Good Manufacturing Practice (GMP) standards for active pharmaceutical ingredient (API) production. This enhancement is a response to a substantial surge in the need for peptide APIs and is aligned with the company's broader strategy for expansion.

Browse 45 Market Data Tables and 36 Figures spread through 162 Pages and in-depth TOC on Global Peptide Synthesis Market, by Product (Reagents & Consumables and Equipment (Peptide Synthesizers, Lyophilizer and Chromatography Equipment)), by Technology (Solid Phase, Liquid Phase and Hybrid and Recombinant), by Application (Therapeutics (Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Infectious Diseases and Others), Diagnosis and Research), by End User (Biopharmaceutical Companies, Contract Development & Manufacturing Organization (CDMO)/Contract Research Organization (CRO), Research Institutes and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/peptide-synthesis-market-4336

Key Takeaways of the Global Peptide Synthesis Market:

• The global peptide synthesis market is expected to exhibit a CAGR of 7.6% during the forecast period, owing to increasing product approval from the U.S. Food and Drug Administration) by market players. For instance, in May 2022, the U.S. Food and Drug Administration announced the approval of Mounjaro (tirzepatide) injections to improve blood sugar control in adults with type 2 diabetes as an addition to diet and exercise. Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
• Among application, therapeutics segment is expected to be the dominant segment in the global peptide synthesis market, owing to the increasing prevalence of various disorders such as metabolic, cardiovascular, and others. For instance, on May 15, 2023, according to a report published by the Centers for Disease Control and Prevention, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S. while one person dies every 33 seconds in the U.S. from cardiovascular disease. About 695,000 people in the U.S. died from heart disease in 2021—that's 1 in every 5 deaths.
• Among regions, North America is expected to be the dominant region in the global peptide synthesis market, owing to the increasing prevalence of people suffering from diabetes in the region, which in turn is expected to drive market growth in this region over the forecast period. For instance, on May 23, 2023, according to a report published by the Centers for Disease Control and Prevention, the prevalence of diagnosed diabetes in the U.S. population for 2021 was found to be approximately 29.7 million, while. 352,000 children and adolescents younger than age 20 years—or 35 per 10,000 US youths-had diagnosed diabetes.
• Major players operating in the global peptide synthesis market include GenScript Biotech Corporation, Merck KGaA, ThermoFisher Scientific Inc., Syngene, Lonza, Novo Nordisk A/S, Bachem Holding AG, Gyros Protein Technologies, Creative Diagnostics, CEM Corporation, PuroSynth, AAPPTec, Biotage AB, AnaSpec, ABclonal, Inc. and Novelgene Technologies